Pre-Clinical Development of a Potent Neutralizing Antibody MW3321 With Extensive SARS-CoV-2 Variants Coverage.

Jiang, Wen; Zhang, Zherui; Zhu, Yuhe; Chen, Ben; Gu, Chunying; Liu, Zhiyan; Zhang, Xukai; Xiong, Hualong; Zhang, Yanan; Zheng, Bin; Wang, Rongjuan; Jiao, Shasha; Wang, An; Zhang, Tianying; Zhang, Jinchao; Wang, Shuang; Zhang, Bo; Li, Gang; Gui, Xun

Jiang, Wen; Zhang, Zherui; Zhu, Yuhe; Chen, Ben; Gu, Chunying; Liu, Zhiyan; Zhang, Xukai; Xiong, Hualong; Zhang, Yanan; Zheng, Bin; Wang, Rongjuan; Jiao, Shasha; Wang, An; Zhang, Tianying; Zhang, Jinchao; Wang, Shuang; Zhang, Bo; Li, Gang; Gui, Xun.

Afiliação

Jiang W; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
Zhang Z; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Zhu Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China.
Chen B; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
Gu C; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
Liu Z; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
Zhang X; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
Xiong H; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China.
Zhang Y; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Zheng B; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
Wang R; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
Jiao S; Beijing Kohnoor Science and Technology Co., Ltd., Beijing, China.
Wang A; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
Zhang T; Beijing Kohnoor Science and Technology Co., Ltd., Beijing, China.
Zhang J; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
Wang S; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China.
Zhang B; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
Li G; Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.
Gui X; Beijing Kohnoor Science and Technology Co., Ltd., Beijing, China.

Front Pharmacol ; 13: 926750, 2022.

Article em En | MEDLINE | ID: mdl-35873586

Palavras-chave

SARS-CoV-2; antibody therapeutics; escape mutation; neutralizing antibody; safety profile

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China